Related Experiment Video
Updated: May 9, 2026

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
Empowering scFv with effector cell functions for improved anticancer therapeutics
1Department of Pathology and Lab Medicine; University of Pennsylvania Perelman School of Medicine; Philadelphia, PA USA.
Abstract:
Single chain variable fragment (scFv) constructs have been an important source of high affinity reagents to target cancer cells. Including an immunoglobulin Fc-binding domain can empower scFvs and other tumor antigen-binding proteins with immune effector cell functions and hence significantly increase their therapeutic potential.
More Related Videos
12:02Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
Published on: November 11, 2021
10:04Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Related Concept Videos
Tumor Immunotherapy
Mitogens and the Cell Cycle
Regulation of Hematopoietic Stem Cells
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...